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Abstract: 
Retrospective studies of silver-coated hip implants have demonstrated promising 
results and safety profile however the potential benefits are so far unproven in 
prospective studies. Silver-coated implants may have a role in patients undergoing 
revision or primary surgery with a high risk of infection but as yet there are no 
human studies investigating silver in primary hip arthroplasty. Adequately 
powered robust prospective studies are needed in this area to determine if silver-
coated implants would be efficacious and cost-effective. The purpose of this 
systematic review article is to review the current literature regarding the use of 
silver in hip arthroplasty. Our review showed that there is some encouraging 
evidence that silver coatings can reduce infection. 
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Introduction 
 
Background 
Silver is a chemical element discovered in approximately 3000BC with an atomic 
number of 47. Its chemical symbol Ag, is derived from the Latin word argentum. 
Silver has a plethora of uses: from jewellery to being woven into gloves, making 
them compatible with touchscreen phones. Its use in Medicine is a function of its 
antimicrobial properties and in this context, it was first used in the eighteenth 
century to treat ulcers [1]. 
 
Mechanism of action of silver 
Silver has activity against bacteria, fungi and viruses [2].  It has been described  as 
“oligodynamic” due to being toxic to bacteria at very low concentrations [3]. The 
mechanism of action is complex and multifaceted. Silver ions are biologically 
active and facilitate the bactericidal effect. Silver ions interact with 3 specific 
bacterial cell structures (Figure 1) [4]. At the peptidoglycan cell wall and plasma 
membrane they cause destruction and cell lysis [5,6]. They interact with bacterial 
DNA preventing DNA replication and thereby reproduction via binary fission. 
They also interact with bacterial proteins, denaturing ribosomes, disabling 
protein synthesis and causing degradation of the plasma membrane [7- 10]. An 
additional mechanism of toxicity to bacteria is through formation of reactive 
oxygen species (ROS) by silver ions. Park et al. have demonstrated ROS- mediated 
silver toxicity with an increased antimicrobial activity in aerobic compared to 
anaerobic conditions [11]. 
 
The multifaceted mechanism reduces the opportunity for the development of 
bacterial resistance in comparison to traditional antibiotics. Current literature 
suggests resistance to silver is rare and sporadic although it is known that silver- 
resistance genes exist in certain types of bacteria.  Randall et al. have discussed 
and try to further elucidate the endogenous (mutational) and exogenous 
(horizontally acquired) mechanisms through which silver resistance has 
developed.{randall et al, journal of antimicrobial chemotherapy, 2015}.  As 
observed by Percival et al. bacterial resistance to antibiotics has occurred in the 
last 70 years but on the contrary, no widespread resistance to silver has developed 
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in over 4 billion years of exposure[12]. 
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Medical application of silver 
Clement and Jarrett comment that the use of silver has been documented since the 
time of the King of Persia using water storage in flagons of silver when going to 
war[3]. Since then, silver has become widespread in different medical 
applications. These include silver-coated catheters [13], municipal water 
systems[14], hospital surfaces disinfection [15] and wound dressings particularly 
in the care of burns[16]. 
 
Silver has been used in both compound forms such as silver nitrate and more 
recently as nanosilver following advancement in manufacturing processes. 
Furthermore, the antimicrobial efficacy of silver has been shown to be related to 
its structural make up, with nanosilver proving more effective than silver chloride 
and silver nitrate [17]. Nanoparticles can be used in coating medical devices, with 
the aim of preventing biofilm formation and technology has developed to enable 
silver to adhere to the surface of a device [18]. This development is of potentially 
huge significance as it allows silver to be used to potentially reduce the risk of 
prosthetic joint infection (PJI) – a complication seen in 1.5-2.5% of all primary hip 
and knee arthroplasty[19]. 
 
Antibiotic prophylaxis therapy is common practice after surgery, but it is difficult 
to demonstrate a clear supremacy of a particular antibiotic over another[20]. The 
most common pathogens associated with post-operative infection are 
staphylococcii yet gram negative organisms such as Pseudomonas Aeruginosa can 
often be very challenging to eradicate given the biofilms produced [21]. By 
introducing prostheses, pathogenic microbes have a surface on which they can 
develop biofilms. Bacteria grow in aggregates that become encased in an 
extracellular matrix produced by the bacteria, where the matrix is often rich in 
polysaccharides, proteins and DNA[22]. They are associated with increased rates 
of infection on human surfaces such as teeth, skin, and the urinary tract, as well as 
medical devices such as catheters, heart valves, and orthopaedic implants[22,23]. 
The biofilm forms a haven for safe growth, making them more difficult to be 
destroyed by the immune system and more resistant to antibiotics[24,25]. 
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This provides the rationale for research into orthopaedic applications of silver, 
such as in tumour prostheses, external fixator pins, bone cement and coating of 
implants[18]. PJI can have devastating effects on a patient’s quality of life[26]. 
Reducing the incidence of PJI would lead to a reduction in the number of revision 
procedures, improved outcomes for patients and reduce the cost to society. In 
bone cement the addition of nanosilver has shown promising in vitro results and 
low levels of toxicity [27]. Similarly, in vitro results of silver coated trauma 
implants have shown promise but with mixed in vivo results [28,29].  Silver has 
been demonstrated to cause toxicity to human tissue, particularly renal, hepatic 
and neural tissues. Additionally local argyria, a blue/purple discoloration of the 
skin, around implants has also been reported.  However clinical studies have so 
far not elucidated any malignant toxicity. The number of silver implants currently 
used are low and sporadic at present. 
 
The purpose of this article is to review the current literature regarding the use of 
silver in hip arthroplasty. 
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Materials and Methods: 
 
Our review team used a rigorous and systematic approach conforming to the 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
and the critical evaluation of studies relating to the use of silver in total hip 
replacement surgery. 
 
Protocol 
A protocol was registered online before commencing the study with PROSPERO 
(International prospective register of systematic reviews, CRD42017082680) as 
recommended by the Quality of Reporting of Meta-analyses (QUOROM) statement 
[30]. 
 
Search strategy 
We searched all studies indexed in OVID MEDLINE, EMBASE, ACM, ADS, arXiv, 
CERN DS, Crossref DOI, DBLP, Espacenet, Google Scholar, Gutenberg, Highwire, 
IEEExplore, Inspire, JSTOR, OAlster, Open Content, Pubget, PubMed, Web of 
Science for the last 10 years using the search strategy shown in Figure 2. The 
search strategy was not limited by language or patient age. We also evaluated the 
grey literature with hand searches of 6 major Orthopaedic journals over the last 5 
years. The bibliographies of the relevant articles were then cross-checked to 
search for articles not identified in the search. The initial screening of studies was 
performed by two independent assessors with any disagreements meaning that 
the study in question was included. An electronic spreadsheet was constructed to 
summarise the findings of relevant studies. 
 
Eligibility criteria 
We included all studies that related to silver implants in hip surgery. 
 
 
 
Screening 
A total of 117 records were identified from the searches described above. The 
titles and abstracts were screened to identify articles for inclusion in this 
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systematic review. After screening 63 articles were assessed for eligibility against 
criteria and from these 11 articles were reviewed formally. A flow diagram of the 
progression of studies through this systematic review is provided in Figure 2. 
 
Data extraction 
Two of the authors worked independently to extract the data using standardized 
forms. We extracted data on participants, joint involved, survivorship of implants, 
prevention of infection and toxicity. 
 
Funding 
This study was supported by the NIHR Biomedical Research Centre at the 
University Hospitals Bristol NHS Foundation Trust and the University of Bristol. 
The views expressed in this publication are those of the author(s) and not 
necessarily those of the NHS, the National Institute for Health Research or the 
Department of Health. 
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Results 
 
There were 63 articles reporting a mix of laboratory studies, animal studies, 
review articles and 11 studies using silver coated implants in patients providing 
level III evidence. Study characteristics are summarised in Table 1. 
 
Endoprosthesis 
Much of the source material gathered around silver-coated prostheses was 
centred on megaendoprosthesis. Endoprostheses are used to address large bone 
defects when conventional prostheses may not suffice. Examples include: major 
osteolysis causing implant loosening, tumours, periprosthetic fractures, or 
periprosthetic infection. Megaendoprostheses are commonly modular, allowing 
intra-operative flexibility, but in contrast to regular prostheses have a larger 
surface area, typically require larger surgical exposures, are used in operations of 
long duration due to the complexity of the indications, and have higher bloods loss 
[31]; all factors associated with an increased risk of PJI. 
 
Revision surgery for tumour endoprostheses has been shown to carry a 
reinfection rate of up to 43%. Often the bacterial biofilm proves too difficult to 
remove and the prosthesis must be removed [32]. Commonly oncological patients 
are immunologically deficient due to chemotherapy, or may be weakened by 
simultaneous disease in other organs, or the malignancy itself, and are at higher 
risk of infection [20]. 
 
In Vitro 
Silver-coated nanotubes have been shown to be effective in preventing biofilm 
formation and lowering bacteria numbers in the early post-operative period [33]. 
In vitro and in vivo evaluations show that nanotubes on titanium surfaces 
encourage osseointegration, cell differentiation, mineralisation, and anti- 
microbial properties (including reducing the initial adhesion and colonisation of 
Staphylococcus epidermidis). Nanotube surface treatment can be applied to 
existing macro and micro porous titanium implants. Nanotubes have been shown 
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to improve bone bonding nine-fold and mineralisation by three times that of non-
treated titanium surfaces[34]. 
 
Thermal sprayed coatings of calcium phosphate containing silver showed 
significant decrease in the adherence of Escherichia Coli, Staphylcoccus Aureus and 
Methicillin-Resistant Staphylococcus Aureus [35]. In megaendoprostheses, silver 
coating may be accomplished by galvanic deposition of elementary silver. This 
first layer is additionally coated with another layer of gold (the cathode) to enable 
continuous release of silver ions (the anode) [21,36]. 
 
Albers et al. investigated silver ion, and nanoparticle, induced cytotoxicity in 
primary osteoblasts (OB) and osteoclasts (OC). They found that the treatment of 
OBs and OCs with silver particles lowered the cell differentiation and number of 
viable cells, OBs more so than OCs; OBs viability being reduced at 128 g/ml silver 
nanoparticles and differentiation being reduced at 64 g/ml, with OCs viability 
and differentiation being reduced at 256 g/ml and 128 g/ml respectively. Dose 
and size also played a key part with nanoparticles (average size 50 nm) being 
more damaging than microparticles (3 m). The bactericidal effects of silver 
occurred at two to four times the levels that induced cytotoxic effects [37]. 
 
Ando et al. found that hamster lung cells grew on the silver calcium phosphate 
coating in a cytotoxicity test [35]. In the presence of hydroxyapatite, silver has a 
much higher photocatalytic activity than titanium oxide-silver mixtures alone, due 
to the generation of free radicals. These free radicals may lead to oxidative stress 
and cell death [24]. 
 
Fielding et al. found that the antibacterial properties of the silver coatings, tested 
against Pseudomonas aeruginosa, were highly effective. They then tested cell- 
material interactions using human foetal osteoblasts in vitro. Cells grown on 
silver-hydroxyapatite surfaces demonstrated dysfunctional features such as 
premature apoptosis, delayed differentiation and cell death, with nearly complete 
impediment of functional alkaline phosphate activity. 
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To combat these effects of silver, strontium was added as a coating mixture acting 
as a binary dopant. The strontium acts to stimulates bone formation, while 
inhibiting bone resorption. By adding strontium oxide to the silver- 
hydroxyapatite mixture they effectively offset the damaging effects and enhanced 
the performance when compared to pure hydroxyapatite coated samples [38]. 
 
In Vivo 
Silver reduces infection in medical devices such as external fixation pins, heart 
valves, endotracheal tubes, and cardiac and urinary catheters [32]. Unlike the 
majority of antibiotics, silver is not limited to one mechanism but can use several: 
blocking the cells respiratory chain, disrupting cell transport, and binding to 
nucleotides and nucleosides of RNA and DNA to limit transcription and translation 
without significant reports of resistance [21]. 
 
Kose et al. used a silver ion-doped calcium phosphate-based ceramic nanopowder 
to look at resistance of bacterial colonisation in knee prostheses in rabbits. They 
inoculated the femoral canals of 27 rabbits with MRSA, and replaced the joints 
after 6 weeks with titanium implants (9 uncoated, 9 hydroxyapatite-coated (HA), 
and 9 silver-coated). Eight of nine uncoated prostheses showed positive cultures, 
five of nine HA were positive, and only one of nine silver-coated prostheses was 
positive [39]. 
 
Gosheger et al. demonstrated in rabbit models that silver levels were elevated in 
silver prostheses, but were within their pre-defined safety parameters with no 
histological change to the organs of the animal [40]. Alongside Hauschild, they 
later demonstrated silver levels in canines. Mean values of silver trace elemental 
concentrations in serum samples ranged from 0.20 to 1.82ppb with baseline data 
representing normal values ranged from 0.20 to 1.38 ppb [41]. Therapeutic 
bactericidal effect can be seen at low concentrations (starting at 35 ppb) whereas 
toxic effects for human cells are expected at much higher concentrations (300–
1200 ppb) [21]. 
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In dentistry, implants have been trialled with antimicrobial coatings such as 
antibiotics and chlorhexidine, but have not been viable due to short-term efficacy 
or cytotoxicity respectively. In addition to silver, strontium, gallium, 
gold/palladium, and zinc alloyed with magnesium have also been found to have 
antimicrobial effects whilst demonstrating biocompatibility [24,42]. Other 
methods of coating include chitosan coating, photoactive-based coatings, 
resorbable antibiotic loaded hydrogels, and silver coatings [21]. 
 
33 patients that received Porag (Porous Argentum) megaprostheses between 
2010 and 2014 were followed up by Scoccianti et al.. The implants were used for 
a variety of reasons including oncological disease, arthroplasty, and trauma. In 
such prostheses the shaft is silver-coated whilst the bone-implant interface in 
general is not. The megaprostheses included proximal, distal and total femurs as 
well as knee arthrodesis prostheses. 3 of the 33 patients developed post-operative 
infections; 1 that had had no previous infection and 2 patients developed 
recurrent infections. Scoccianti displayed no local or systemic side effects [43]. 
 
Donati et al. followed up 68 patients with primary or metastatic proximal femur 
bone tumours. Of the 18% that required further surgery, 13% were due to 
infection. Patients that had been given silver-coated prostheses developed early 
infection (under 6 months after surgery) in 2% of cases, whereas standard tumour 
prostheses developed early infection in 11% of cases. Late infection (occurring 
after six months) occurred at similar rates in both groups. Two silver- coated 
prostheses removed at 27 and 82 months after surgery showed near total absence 
of silver. Bloods taken at various times after surgery showed serum silver levels 
to be significantly below the toxic threshold, and no patients exhibited any 
symptoms of silver toxicity. Donati reported no local or systemic side effects [44]. 
 
Over a 10-year period, Wafa et al. matched 85 patients with Algluna-treated 
tumour implants (silver-coated megaendoprosthesis) with 85 identical, but 
uncoated, tumour prostheses. The infection rate in uncoated prostheses was 
almost double, with Agluna infection rates at 11% and the control at 22% 
(p=0.033). 7 of the infected 
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10 Agluna prostheses were treated with debridement and implant retention and 
antibiotics, versus 6 of the 19 control implants; 70% versus 32% respectively. 
Chronic infection rates were found to be 4% in the silver group, and 15% in the 
control group. Wafa reported no local or systemic side effects and commented that 
the Agluna prosthetic uses less silver in its coating than traditional prostheses 
(less than 2% of the lowest estimate of Hardes’ prosthesis) [45]. 
 
In 2010, Hardes et al. compared the infection rate between silver-coated and 
titanium megaprostheses. The silver group consisted of 51 patients (22 proximal 
femur, 29 proximal tibia) and the titanium group 74 patients (33 proximal femur, 
41 proximal tibia). 6% of those that received silver implants developed 
periprosthetic infection, compared to 18% of those that received titanium 
implants. Infection rates were decreased in the silver prostheses. 5 patients 
ultimately underwent amputation due to infected proximal tibia prostheses, 
whereas none to that received a silver implant had undergone amputation. One 
patient of Hardes (a silver-coated prostheses patient) presented 50 months 
postoperatively with a blue-grey discolouration of the skin over the area operated 
on. The differential diagnoses were known varicosis with venous insufficiency and 
suspected local argyrosis [32]. In an analysis of 56 patients  that received silver 
implants for proximal tibia replacement in sarcoma; 4 were alive with disease 
(7%), and 5 dead of disease (9%), and of the 42 that received titanium 2 were alive 
with disease (5%), and 9 were dead of disease (21%) [46]. 
 
Toxicity 
Given the known problems with metal ion toxicity following metal-on-metal 
arthroplasty, there is concern about potential toxicity of silver. Silver 
nanoparticles can cause toxic effects to human tissues [47] and there is evidence 
of an immunosuppressive effect [48]. Silver nanoparticle-mediated cytotoxicity to 
mesenchymal stem cells and osteoblasts has been shown to occur at higher 
concentrations, with the inference that a therapeutic window is likely to exist [49]. 
Necula et al. looked at the cytotoxicity of different concentrations of silver 
nanoparticles on an implant surface against a human osteoblastic cell line and 
found an optimum cell growth combined with antibacterial effect at certain 
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concentrations [50]. However it has been demonstrated that  antibacterial  effects 
of silver occur at levels higher than those which induce cytotoxic effects, and 
indeed the authors commented that their study provides evidence of potential 
problems associated with orthopaedic implants [37]. In their review, Brennan et 
al. comment that further research is required to find a method of controlling 
release of nanoparticles from an implant so that it is compatible with the host as 
well as providing antibacterial activity [18]. Silver toxicity may occur at serum 
levels as low as 0.3mg/mL and present as argyria and leukopenia, as well as 
causing alterations in renal, hepatic, and neural tissues [20]. The minimum doses 
mentioned in the literature to cause argyria are approximately 4–6g [51]. 
 
Glehr et al. followed up 31 patients that underwent megaendoprostheses for 
infection or resection of malignant tumours between 2004 and 2011. Levels of 
silver locally in drains and seromas were measured. 7 patients (23%) developed 
local argyria (median 25 months). No malignant symptoms of silver poisoning 
(neurological/ renal/ hepatic) were found. They stated that local argyria is 
generally benign, although fairly irreversible. The size of the implant was not 
associated with argyria. Patients with and without argyria, both had similar levels 
of serum silver [52]. 
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Discussion 
 
Silver has established antimicrobial properties. By interacting with the cell wall, 
plasma membrane, DNA and RNA silver ions can cause cell lysis. Its widespread 
effects and low resistance rates make it a good candidate for use in hip 
arthroplasty. Silver is a versatile material and is relatively easy to apply to 
implants, where the risk of biofilm formation is high, it can help to reduce the risk 
of prosthetic joint infection. 
 
In vitro case demonstrate promise. The antimicrobial effects of silver are 
reproduced in cell cultures and are effective against Staphylococcus epidermis (the 
most common bacteria to colonise prostheses), Staphylococcis aureus, 
Pseudomonas aeruginosa, and Escherichia coli. However, silver demonstrates 
cytotoxic effects at the cellular level, inhibiting osteoblast and osteoclast 
performance. This osteoblastic cytotoxicity presents concerns about the longevity 
of implant fixation and, secondarily, revision for loosening. This effect could 
potentially be reduced with the addition of other elements such as strontium that 
act to stimulate osteoblast and osteoclast cells. Alternatively the silver coating 
could be localized away from the implant-bone interface such as adjacent to the 
hip articulation itself. 
 
Silver is used to reduce the risk of infection in implants and devices such as 
catheters and stents. The majority of the data published in relation to silver- 
coated orthopaedic implants involves megaendoprostheses used in tumour 
surgery. Silver’s antibacterial properties are attractive in patients that may be 
immunocompromised due to disease or chemotherapy. The included studies 
indicate that infection rates in the post-operative period were lower in those that 
had received silver-coated implants over controls. It is difficult to pinpoint the 
level at which silver may cause serious local or systemic damage. Most of the cases 
had no significant side effects from silver, though trace elements of silver  in the 
blood were often raised but below the toxic threshold. Local argyria occurred in a 
small number of cases but did not seem to cause any systemic upset. 
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Conclusion 
 
Silver has antimicrobial properties. It is easily applied to implants and has shown 
efficacy in smaller devices or implants. In vitro studies of silver have shown signs 
of cell toxicity, but it does not seem to cause systemic upset in in vivo studies. The 
available literature is predominated by silver coated megaendoprostheses used in 
malignancy or recurrent infection; in this context, it has proved effective in 
reducing infection rates. There is no randomised trial evidence of its use in 
primary hip arthroplasty. Furthermore silver coated primary implants would 
need to be monitored closely via the National Joint Registries. 
 
The potential benefits of silver-coated hip implants are so far unproven in 
prospective studies. Retrospective studies have demonstrated promising results 
and safety profile. Silver coated hip implants may have a role in patients 
undergoing revision or primary surgery with a high risk of infection. Prospective 
robust studies are needed in this area to determine if silver-coated implants would 
be efficacious and cost-effective in this setting. 
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Figure Legends: 
 
Figure 1: Illustration of the mechanisms of action of silver ions [4] 
Figure 2: PRISMA flow diagram 
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Table 1: Characteristics of included studies 
 
Author Journal/year Study 
type/Level of 
evidence 
Number of 
patients 
Implant Indication/context Evidence of 
infection 
prevention 
Risk/safety 
Ando et al. [35] Calcium 
phosphate coating 
containing silver shows 
high antibacterial activity 
and low cytotoxicity and 
inhibits bacterial adhesion 
Materials 
Science and 
Engineering: 
C 
2010 
Laboratory 
study 
- Novel coating 
technology of 
calcium 
phosphate 
containing 
silver, using 
thermal 
spraying 
technique 
Evaluated 
antibacterial efficacy 
and biological safety 
of coating. 
In vitro 
antibacterial 
activity showed 
growth of bacteria 
to be completely 
suppressed. 
Animal cells 
were found 
to grow on 
the coating in 
a cytotoxicity 
test. 
Chen et al. [53] Silver 
release from silver- 
containing hydroxyapatite 
coating. 
Surface and 
Coatings 
Technology 
2010 
Laboratory 
study 
- Silver- 
containing 
hydroxyapatite 
coatings were 
prepared by 
coprecipitation 
or plasma 
spraying 
Behaviour of silver 
release from 
composite coating in 
buffering fluid and 
simulated body fluid 
monitored. 
Rate of release of 
silver particles was 
higher for 
coprecipitation 
method compared 
to plasma spraying. 
Phase composition 
and surface 
morphology of 
coatings may affect 
their bioactive 
properties. 
- 
Hardes et al. [32] 
Reduction of 
periprosthetic infection 
with silver-coated 
megaprostheses in 
patients with bone 
sarcoma. 
Journal of 
Surgical 
Oncology 
2010 
Prospective 
cohort (silver 
group) . 
Retrospective 
cohort (titanium 
group) 
125 
(Silver = 51 
Titanium = 74) 
MUTARS 
proximal femur 
and proximal 
tibia 
replacement 
Proximal femur/tibia 
sarcoma requiring 
replacement. 
Incidence of 
periprosthetic 
infection reduced 
from 17.6% to 
5.9% (p=0.062). 
1 case of 
suspected 
local 
argyrosis 50 
months 
postoperativ 
ely 
Mondanelli et al. [54] 
Modular prosthesis with a 
Journal of 
Orthopaedic 
Case series 10 MegasystemC 
with a silver 
Septic arthroplasty 
(4), septic meta- 
Preliminary results 
demonstrate 
No comment. 
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silver coating for Traumatolog   coating epiphyseal post- resolution of  
periarticular y (In-depth  traumatic deformity infection in all 
reconstruction in septic oral  of non union (5), cases. 
prosthetic and post- presentations  epithelioid hemangio-  
traumatic failures. and oral  endothelioma (1)  
 communicati    
 ons)    
 2012    
Trujilo et al. [55] Materials Laboratory - Plain titanium, Bacterial adhesion Less bacteria - 
Antibacterial effects of Science and study  titanium study adhere to surfaces  
silver-doped Engineering:   coated with  containing  
hydroxyapatite thin films C   hydroxyapatite  hydroxyapatite and  
sputter deposited on 2012   , titanium  silver  
titanium    coated with    
    silver-doped    
    hydroxyapatite    
Swieczko-Zurek B [25] Advances in Laboratory  Polymer vein In vitro study. Strong protection - 
The influence of biological Material study implant  against biofilm  
environment on the Sciences  covered with  production in  
appearance of silver- 2012  silver and  polymer and  
coated implants.   stainless steel  metallic implants.  
   intramedullary    
   nail covered    
   with silver    
Kose et al. [39] A silver Clinical Animal study 27 (9 uncoated Titanium  Silver ion-doped No cellular 
ion-doped calcium Orthopaedics  9 hydroxapatite implants ceramic inflammation 
phosphate-based ceramic and Related  coated  nanopowder of foreign- 
nanopowder-coated Research  9 silver coated)  coating of titanium body 
prosthesis increased 2013    implants led to an granuloma 
infection resistance     increase in was observed 
     resistance to around the 
     bacterial silver-coated 
     colonization prostheses. 
     compared to  
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      uncoated implants  
Zimmerli W. [56] Clinical 
presentation and 
treatment of orthopaedic 
implant-associated 
infection. 
Journal of 
Internal 
Medicine 
2014 
Review - - - Antimicrobial 
agents have limited 
efficacy against 
biofilm infections; 
novel preventative 
options are 
needed. 
Prevention may be 
achieved in the 
future by implant 
coating with novel 
substances. 
- 
Brennan et al. [18] Silver 
nanoparticles and their 
orthopaedic applications. 
The Bone and 
Joint Journal 
2015 
Review - - - Silver nanoparticle 
technology in 
orthopaedic 
devices has great 
potential to reduce 
implant infection. 
Further 
research 
warranted, 
particularly 
to elucidate 
potential 
harmful 
effects. 
Wafa et al. [45] 
Retrospective evaluation 
of the incidence of early 
periprosthetic infection 
with silver-treated 
endoprostheses in high 
risk patients: case-control 
study. 
The Bone and 
Joint Journal 
2015 
Retrospective 
case-control 
170 
(Silver = 85 
Titanium = 85 
Agluna-treated 
tumour 
implants vs 
uncoated 
implants 
50 primary 
reconstructions, 79 
one-stage revisions 
and 41 two-stage 
revisions 
Overall post op 
infection rate 
11.8% in silver 
group vs 22.4% in 
control group 
(p=0.033) 
No comment 
Donati et al. [44] Silver 
coated prosthesis in 
oncological limb salvage 
surgery reduce the 
infection rate. 
Journal of 
Biological 
Regulators 
and 
Homeostatic 
Agents 
Retrospective 
case-control 
158 Silver coated vs 
non silver 
coated 
Primary or metastatic 
bone tumours treated 
with excision and 
tumour implant 
reconstruction 
Early infection: 
2.2% with silver 
implant vs 10.7% 
with standard. 
No evidence 
of silver 
toxicity 
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 2015       
Donati et al. [57] Silver- 
coated hip prosthesis 
reduce the infection rate 
in oncological limb salvage 
surgery. 
Abstracts 
from 
International 
Combined 
Meeting BHS- 
SldA 
26-27 
November 
2015 
Retrospective 
cohort 
68 Silver coated vs 
non silver 
coated 
Primary or metastatic 
proximal femur bone 
tumours treated with 
excision and tumour 
implant 
reconstruction 
Early infection: 
2.2% with silver 
implant vs 10.7% 
with standard. 
Similar rate of 
infection at 6 
months. 
No evidence 
of silver 
toxicity 
Eto et al. [58] First Clinical 
Experience with Thermal- 
Sprayed Silver Oxide- 
containing Hydroxyapatite 
coating implant. 
Primary 
Arthroplasty 
2015 
Prospective case 
series 
20 AMS HA Cup 
and 910 PerFix 
Fullcoat D stem 
thermal 
sprayed with 
silver 
Inclusion criteria: Age 
≥ 65 and an indication 
for THA 
Harris Hip Scores 
were improved 
after surgery in 
line with 
traditional 
implants. 
1 hip 
dislocation at 
6 weeks. 4 
cases showed 
detectable 
spot welds at 
1 year X-ray. 
No argyria or 
neurologic 
symptoms. 
No infections. 
Furko et al. [59] Complex 
electrochemical studies on 
silver-coated metallic 
implants for orthopaedic 
application 
Journal of 
Solid State 
Electrochemi 
stry 
2015 
Laboratory 
study 
- Silver grains 
deposited onto 
different 
implant 
materials 
common used 
in orthopaedic 
surgery 
Electrochemical 
behaviour of the 
coating and silver ion 
release rate were 
investigated 
  
Furko et al. [60] 
Comparative corrosion 
study on silver coated 
metallic implants 
Material 
Science 
Forum 
2015 
Laboratory 
study 
- Nanostructure 
d silver layer 
was deposited 
onto different 
implant 
Electrochemical 
behaviour of the 
coatings investigated 
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    materials 
common used 
in orthopaedic 
surgery 
   
Amin Yavari et al. [33] 
Antibacterial behaviour of 
additively manufactured 
porous titanium with 
nanotubular surfaces 
releasing silver ions. 
ACS Applied 
Materials and 
Interfaces 
2016 
Laboratory 
study 
- Titanium 
nanotubes 
loaded with 
silver 
Antimicrobial activity 
and cell viability of 
developed material 
were assessed. 
Silver loaded 
nanotubes 
extremely effective 
in preventing 
biofilm formation. 
Specimens 
with highest 
concentratio 
ns of silver 
adversely 
affected cell 
viability 
Funao et al. [23] A novel 
hydroxyapatite film coated 
with ionic silver via 
inositol hexaphosphate 
chelation prevents 
implant-associated 
infection. 
Scientific 
Reports 
2016 
Animal trial. 10 (Silver = 5 
Titanium = 5) 
Hydroxyapatite 
film coated 
ionic silver vs 
titanium 
implant 
In vivo study: 
antibacterial effects of 
ionic-silver coating in 
a murine model of 
implant-associated 
osteomyelitis. 
No bacteria 
detectable after 
inoculation. Serum 
IL-6 reduced. CRP 
reduced. 
No comment 
Donati et al. [20] Silver- 
coated hip megaprosthesis 
in oncological limb salvage 
surgery. 
BioMed 
Research 
International 
2016 
Retrospective 
cohort 
68 Silver-coated 
hemiarthroplas 
ty (MUTARS) 
vs uncoated 
megaprosthese 
s 
Primary or metastatic 
bone tumour proximal 
femur 
Early infection 
2.6% vs 10% (not 
statistically 
significant) 
No evidence 
of silver 
toxicity 
Scoccianti et al. [43] Levels 
of silver ions in body fluids 
and clinical results in 
silver-coated 
megaprostheses after 
tumour, trauma or failed 
arthroplasty. 
Injury 
2016 
Retrospective 
case series 
33 MegasystemC 
with a silver 
coating 
A silver-coated 
prosthesis was chosen 
for the following 
causes: septic failure 
of previous 
megaprosthesis: 8 
patients. Septic 
complication after 
fracture: 7 patients. 
Septic failure of 
previous standard 
There was no 
infection during 
the first two years 
after surgery in the 
12 patients who 
received a silver- 
coated 
megaprosthesis 
and had no 
previous history of 
No evidence 
of silver 
toxicity 
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     joint arthroplasty: 6 
patients. Oncological 
resection with patient 
at particular risk of 
infection 
complication: 8 
patients. Non- 
oncological resection 
with patient at 
particular risk of 
infection 
complication: 4 
patients. 
infection. Infection  
recurred in 2 out of 
21 patients who 
had received the 
implant because of 
previous septic 
complications. 
Besinis et al. [24] 
Antibacterial activity and 
biofilm inhibition by 
surface modified titanium 
alloy medical implants 
following application of 
silver, titanium dioxide 
and hydroxyapatite 
nanocoatings 
Nanotoxicolo 
gy 
2017 
Laboratory 
study 
 Titanium alloy 
implants 
modified to 
create silver, 
titanium oxide 
and 
hydroxyapatite 
coatings 
In vitro study. 
Antibacterial 
performance assessed 
Silver coating 
inhibited bacterial 
growth in 
surrounding media 
and bacterial 
biofilm production 
reduced by 97.5% 
- 
Devlin-Mullin et al. [42] Advanced Laboratory   In vitro and in vivo Bacterial growth Strong 
Atomic layer deposition of Healthcare study study. slower on silver adherence 
a silver nanolayer on Materials   coated titanium and growth 
advanced titanium 2017   scaffolds. Also of human 
orthopaedic implants    reduced bacterial bone or 
inhibits bacterial    recovery and endothelial 
colonization and supports    biofilm formation. cells in 
vascularized de novo bone     titanium and 
ingrowth     silver coated 
     implants. 
Nandi et al. [61] Silver 
nanoparticle deposited 
Journal of 
Biomedical 
Animal study 15 (rabbits) Silver coated 
pins 
Osteomyelitis rabbit 
model 
Silver coated pins 
offered promising 
No toxicity to 
major organs 
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implants to treat 
osteomyelitis 
Materials 
Research Part 
B 
2017 
    result in terms of 
eradication of 
infection in rabbit 
osteomyelitis 
model 
 
Schmidt-Braekling et al. European Review - - - Evidence of Several side 
[21] Silver –coated Journal of     potential benefit of effects 
megaprostheses: review of Orthopaedic     silver coated reported in 
the literature Surgery and     megaprostheses so earlier 
 Traumatolog     far not been studies but 
 y     confirmed in most recent 
 2017     prospective and studies have 
      randomized confirmed 
      studies alone. lack of 
      Reduced infection systemic 
      rate seen in toxicity to 
      retrospective silver. 
      studies.  
Schmolders et al. [62] The Zeitschrift Retrospective 25 MUTARS Patients undergoing Good clinical and - 
role of a modular Fur case series   revision surgery for functional results.  
universal tumour and Orthopadie    failed endoprosthetic High rates of  
revision system (MUTARS) Und    replacement or failed infection.  
in lower limb Unfallchirurgi    trauma surgery, using   
endoprosthetic revision e    MUTARS   
surgery – outcome 2017       
analysis of 25 patients        
Schmolders et al. [63] Archives of Case series 100  Tumour-related lower 10% suffered No evidence 
Lower limb reconstruction Orthopaedic   limb salvage surgery periprosthetic of silver 
in tumour patients using and Trauma    infection toxicity 
modular silver-coated Surgery      
megaprostheses with 2017      
regard to       
perimegaprosthetic joint       
infection: a case series,       
including 100 patients and       
24 
 
 
 
 
 
review of the literature        
Volker A. [36] Injury Review - - - Low amount silver High amount 
Antimicrobial coated 2017     Agluna silver coating 
implants in trauma and      technologies have associated 
orthopaedics – A clinical      shown the “proof with local 
review and risk-benefit      of concept” for argyria. 
analysis.      antimicrobial Further data 
      coatings of from 
      implants with good randomizes 
      risk benefit ratio. controlled 
       trials 
       desirable. 
Zajonz et al. [31] Silver- BMC Retrospective 34 (14 non- MML Munchen- All patients fitted with Reinfection rate No comment. 
coated modular Musculoskele cohort silver coated Lubeck modular after healed  
Megaendoprostheses in tal Disorders  group modular endoprosthesis of reinfection in silver  
salvage revision 2017  20 silver-coated endoprosthesis lower extremity after group was 40%  
arthroplasty after   group) system vs a cured bone infection compared to 57%  
periimplant infection with    MUTARS  in non silver group.  
extensive bone loss – a      Not statisticially  
pilot study of 34 patients      significant.  
Origin-One and Logical-      These devices are  
One Clinical Evidence safe and effective 
Evaluation Report for their intended 
 use. Warrant 
 further clinical 
 research to 
 establish their 
 effectiveness in a 
 total hip 
 replacement 
 procedure and in 
 reducing 
 periprosthetic 
 infection. 
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